ASCO 2024

Article collection

We are proud to present a special collection of articles for the American Society of Clinical Oncology Annual Meeting 2024. This curated selection showcases the cutting-edge advancements and novel perspectives published in journals from Elsevier's Oncology Journal Network. We invite you to explore this collection and delve deeper into the exciting advancements shaping the future of cancer research.

Annals of Oncology

• Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040 打開新的分頁／視窗

• Timing of Radiotherapy (RT) After Radical Prostatectomy (RP): Long-term outcomes in the RADICALS-RT trial [NCT00541047] 打開新的分頁／視窗

Blood Neoplasia

• Patients with Castleman disease report mild COVID-19 symptoms and mount a humoral response to SARS-CoV-2 vaccination 打開新的分頁／視窗

Cancer Epidemiology

• Risk factors for early-onset colorectal cancer: A Canadian prospective cohort study 打開新的分頁／視窗

• Metformin’s role in lowering colorectal cancer risk among individuals with diabetes from the Southern Community Cohort Study 打開新的分頁／視窗

Cancer Letters

• Organoid: Bridging the gap between basic research and clinical practice 打開新的分頁／視窗

• SPOP-mutant prostate cancer: Translating fundamental biology into patient care 打開新的分頁／視窗

Cancer Pathogenesis and Therapy

• PI3K/AKT/mTOR pathway, hypoxia, and glucose metabolism: Potential targets to overcome radioresistance in small cell lung cancer 打開新的分頁／視窗

• Distinct T helper cell-mediated antitumor immunity: T helper 2 cells in focus 打開新的分頁／視窗

• Clinical characteristics and treatment outcomes of Chinese diffuse large B-cell lymphoma patients in the era of rituximab (2005–2018) 打開新的分頁／視窗

Cancer Treatment Reviews

• Waiting for the “liquid revolution” in the adjuvant treatment of colon cancer patients: a review of ongoing trials 打開新的分頁／視窗

• First-line combination treatment with PARP and androgen receptor–signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States 打開新的分頁／視窗

Clinical Breast Cancer

• Unlocking the Power of the Homing Phenomenon: Why Breast Conserving Surgery Outshines Mastectomy in Overall Survival 打開新的分頁／視窗

• Robotics in Screening, Diagnosis and Treatment of Breast Cancer: A Perspective View 打開新的分頁／視窗

• Risk of Recurrence in Patients With HER2+ Early-Stage Breast Cancer: Literature Analysis of Patient and Disease Characteristics 打開新的分頁／視窗

Clinical Colorectal Cancer

• Adjuvant Chemotherapy for Older Patients With Stage III Colorectal Cancer: A Real-World Analysis of Treatment Recommendations, Treatment Administered and Impact on Cancer Recurrence 打開新的分頁／視窗

• Consideration of Metastasis-Directed Therapy for Patients With Metastatic Colorectal Cancer: Expert Survey and Systematic Review 打開新的分頁／視窗

• A Case of Heavily Pretreated HER2+ Colorectal Liver Metastases Responsive to Hepatic Arterial Infusion Chemotherapy 打開新的分頁／視窗

Clinical Genitourinary Cancer

• Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant Prostate Cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy 打開新的分頁／視窗

• Cystic Pelvic Masses in Men: A Presentation of Uncommon Cases and a Literature Review 打開新的分頁／視窗

• The Impact of Blue Light Cystoscopy Use Among Nonmuscle Invasive Bladder Cancer Patients in an Equal Access Setting: Implications on Recurrence and Time to Recurrence 打開新的分頁／視窗

Clinical Lung Cancer

• Lung Cancer in Women: The Past, Present, and Future 打開新的分頁／視窗

• Perioperative Immunotherapy for Non-Small Cell Lung Cancer: Practical Application of Emerging Data and New Challenges 打開新的分頁／視窗

• Personalised Assessment and Rapid Intervention in Frail Patients With Lung Cancer: The Impact of an Outpatient Occupational Therapy Service 打開新的分頁／視窗

Clinical Lymphoma Myeloma and Leukemia

• Recommendations for Management of Secondary Antibody Deficiency in Multiple Myeloma 打開新的分頁／視窗

• Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial 打開新的分頁／視窗

• Optimizing the CAR T-Cell Therapy Experience in Multiple Myeloma: Clinical Pearls From an Expert Roundtable 打開新的分頁／視窗

Clinics

• Delayed diagnosis and increased mortality risk: Assessing the effects of the COVID-19 pandemic on breast cancer recurrence 打開新的分頁／視窗

• Health-Related quality of life by 31-item Cervantes scale in breast cancer survivors undergoing adjuvant endocrine therapy 打開新的分頁／視窗

• Prolonged survival after thoracic metastasectomy in patients with nonseminomatous testicular cancer 打開新的分頁／視窗

Critical Reviews in Oncology/Hematology

• A practical algorithm for acute myeloid leukaemia diagnosis following the updated 2022 classifications 打開新的分頁／視窗

• Oncogenic fusions: Targeting NTRK 打開新的分頁／視窗

• Unraveling molecular signatures in rare bone tumors and navigating the cancer pathway landscapes for targeted therapeutics 打開新的分頁／視窗

ESMO Gastrointestinal Oncology

• Benefits from early trial involvement in metastatic colorectal cancer: outcomes from the phase I unit at the Sarah Cannon Research Institute UK 打開新的分頁／視窗

• Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to KRAS mutational status 打開新的分頁／視窗

ESMO Open

• Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial 打開新的分頁／視窗

• Antibody–drug conjugates are active in patients with HER2-positive breast cancer brain metastases: where do we go from here? 打開新的分頁／視窗

ESMO Real World Data and Digital Oncology

• Toward optimizing patient selection for EGFR antibody therapies in metastatic colorectal cancer: outcomes and resistance features in real-world data 打開新的分頁／視窗

• Real-world patterns of treatment and response in metastatic renal cell carcinoma: a multicentre UK-wide review with UK Renal Oncology Collaborative (UK ROC) 打開新的分頁／視窗

Gynecologic Oncology

• Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: Addressing implementation challenges - 2023 update 打開新的分頁／視窗

• Associations of metformin therapy treatment with endometrial cancer risk and prognosis: A systematic review and meta-analysis 打開新的分頁／視窗

• Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer 打開新的分頁／視窗

• A personalized probabilistic approach to ovarian cancer diagnostics 打開新的分頁／視窗

Gynecologic Oncology Reports

• Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine 打開新的分頁／視窗

• The challenging journey of cervical cancer diagnosis and treatment at the second largest hospital in Indonesia 打開新的分頁／視窗

• Quality corner: Safely using cephalosporins in almost all patients with penicillin allergies: Mini-review and suggested protocol to improve efficacy and surgical outcomes 打開新的分頁／視窗

• Ovarian cancer think tank: An overview of the current status of ovarian cancer screening and recommendations for future directions 打開新的分頁／視窗

Immuno-Oncology and Technology

• Immune biomarker evaluation of sequential tyrosine kinase inhibitor and nivolumab monotherapies in renal cell carcinoma: The phase 1 TRIBE trial 打開新的分頁／視窗

• Engineering approaches for innate immune-mediated tumor microenvironment remodeling 打開新的分頁／視窗

Journal of Cancer Policy

• Implications of FDA’s marketing authorization of hereditary cancer testing 打開新的分頁／視窗

• INDIGO: Example of inappropriate crossover and why PFS cannot be the primary outcome in gliomas 打開新的分頁／視窗

Journal of the National Cancer Center

• Cancer incidence and mortality in China, 2016 打開新的分頁／視窗

• Patterns and trends in esophageal cancer incidence and mortality in China: An analysis based on cancer registry data 打開新的分頁／視窗

• The roles of histone modifications in tumorigenesis and associated inhibitors in cancer therapy 打開新的分頁／視窗

Journal of Thoracic Oncology

• Read here for the Journal of Thoracic Oncology ASCO articles. 打開新的分頁／視窗

Leukemia Research

• CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123 打開新的分頁／視窗

• Identification of unique molecular heterogeneity of human CD79, the signaling component of the human B cell antigen receptor (BCR), and synergistic potentiation of the CD79-targeted therapy of B cell tumors by co-targeting of CD79a and CD79b 打開新的分頁／視窗

• The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms 打開新的分頁／視窗

Leukemia Research Reports

• Successful anti-tumor effects with two novel bifunctional chemotherapeutic compounds that combine a LAT1 substrate with cytotoxic moieties in aggressive T-cell lymphomas 打開新的分頁／視窗

• Myeloid neoplasms in inflammatory bowel disease: A case series and review of the literature 打開新的分頁／視窗

• Long-term follow-up of efficacy and safety in elderly patients with chronic myeloid leukemia treated with intermittent low dose dasatinib therapy 打開新的分頁／視窗

Magnetic Resonance Imaging

• Delineation of the internal iliac vein using MRI with true FISP sequence in patients with locally recurrent rectal cancer: A pilot study using CT/MRI fusion 打開新的分頁／視窗

Neoplasia

• Interdisciplinary care of children with diffuse midline glioma 打開新的分頁／視窗

Oral Oncology

• HER2-targeted therapies for salivary gland cancers 打開新的分頁／視窗

• Longitudinal post-radiotherapy plasma Epstein-Barr virus DNA trends inform on optimal risk stratification in endemic nasopharyngeal carcinoma 打開新的分頁／視窗

Oral Oncology Reports

• Salivary exosomes as biomarkers for early diagnosis of oral squamous cell carcinoma 打開新的分頁／視窗

Radiation Medicine and Protection

• Comparison of pencil beam and Monte Carlo calculations with ion chamber array measurements for patient-specific quality assurance 打開新的分頁／視窗

• Alzheimer's disease and low-dose radiation therapy: A new hope 打開新的分頁／視窗

• Expert consensus on radiotherapy combined with immunotherapy for esophageal cancer (2024 edition) 打開新的分頁／視窗

Seminars in Oncology

• PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics 打開新的分頁／視窗

• PARP inhibitors for prostate cancer 打開新的分頁／視窗

Surgical Oncology Insight

• The effect of the pandemic on colorectal cancer in the United States: an increased disease burden 打開新的分頁／視窗

• Assessing the OPRA Trial for surgical oncologists: Safety and feasibility of a total neoadjuvant therapy approach in patients with rectal cancer 打開新的分頁／視窗

• Malignant Bowel Obstruction: Historical Lessons, Current Trends, and Future Directions 打開新的分頁／視窗

• Implementation of the 2015 American Thyroid Association Guideline Changes Across a Health System: A Quality Improvement Opportunity 打開新的分頁／視窗

The Breast

• Platinum chemotherapy for early triple-negative breast cancer 打開新的分頁／視窗

• Effectiveness of hybrid digital breast tomosynthesis/digital mammography compared to digital mammography in women presenting for routine screening at Maroondah BreastScreen: Study protocol for a co-designed, non-randomised prospective trial 打開新的分頁／視窗

• Diagnostic delays in breast cancer among young women: An emphasis on healthcare providers 打開新的分頁／視窗

The Journal of Liquid Biopsy

• Technical evaluation of a novel digital PCR platform for detecting EGFR/KRAS mutations in NSCLC archived plasma specimens 打開新的分頁／視窗

• Liquid biopsy: Cell-free DNA based analysis in breast cancer 打開新的分頁／視窗

• New perspectives on inoperable early-stage lung cancer management: Clinicians, physicists, and biologists unveil strategies and insights 打開新的分頁／視窗

ESMO Podcasts

Listen to the most recent podcasts from the ESMO portfolio.

🎙️ ADCs in HER2+ metastatic breast cancer brain metastases - ESMO Podcasts 打開新的分頁／視窗

🎙️ Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer by ESMO Podcasts (soundcloud.com)

Oncology journal network

We’ll help you find the right home for your research – fast

Publishing your work can be time-consuming, especially if the first journal you submit to isn’t right for your research. With over 40 journals, including The Lancet Oncology, Cancer Cell, European Journal of Cancer and Cancer Letters,  Elsevier’s Oncology Journal Network 打開新的分頁／視窗 has the right home for your research. And with our transfer service, you’ll benefit from a smooth, simple publishing process.